ANTH Anthera Pharmaceuticals Inc.

1.64
+0.10  (6%)
Previous Close 1.54
Open 1.54
Price To book 4.21
Market Cap 17886532
Shares 10,906,422
Volume 260,536
Short Ratio 4.07
Av. Daily Volume 458,981

SEC filingsSee all SEC filings

  1. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 171097775
  2. 8-K - Current report 171053475
  3. 8-K - Current report 171018810
  4. 8-K - Current report 171018520
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017615

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due end of 2017 or early 2018.
Sollpura - RESULT
Exocrine pancreatic insufficiency
Phase 2 primary endpoint not met following interim analysis. Trial to continue. Top-line data released August 28, 2017.
Blisibimod
IgA nephropathy
Top-line data released December 27, 2016 - missed primary endpoint.
Sollpura (liprotamase)
Cystic fibrosis who suffer from exocrine pancreatic insufficiency
Phase 3 trial did not meet endpoints - November 10, 2016.
Blisibimod
Lupus

Latest News

  1. 4 health stocks and a gamer in the Blitz
  2. Is There Now An Opportunity In Anthera Pharmaceuticals Inc (ANTH)?
  3. Today's Research Reports on Trending Tickers: Anthera Pharmaceuticals and NewLink Genetics
  4. Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis
  5. Anthera Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference
  6. Anthera Pharmaceuticals to Participate in the Citi 12th Annual Biotech Conference
  7. Anthera's Blisibimod Positive in Phase II Extension Study
  8. Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
  9. Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network
  10. Today's Research Reports on Trending Tickers: DryShips and Anthera Pharmaceuticals
  11. Anthera beats 2Q profit forecasts
  12. Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
  13. Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results
  14. Anthera reports 1Q loss
  15. Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2%

SEC Filings

  1. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 171097775
  2. 8-K - Current report 171053475
  3. 8-K - Current report 171018810
  4. 8-K - Current report 171018520
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017615
  6. 8-K - Current report 17966042
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17959270
  8. 8-K - Current report 17919266
  9. 424B5 - Prospectus [Rule 424(b)(5)] 17919257
  10. 424B5 - Prospectus [Rule 424(b)(5)] 17918239